Overview of Relapsed/Refractory Multiple Myeloma

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

Now Viewing

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Usmani distinguishes between relapsed and refractory multiple myeloma. Refractory disease progresses on therapy, whereas relapsed disease recurs after a treatment-free interval of at least 2 months. Management involves selecting optimal regimens based on patient and disease factors and prior treatment tolerance. If disease is triple-class refractory, options narrow but new targets such as BCMA and GPRC5D enable chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies. Two CAR T-cell products targeting BCMA are approved: idecabtagene vicleucel and ciltacabtagene autoleucel. Bispecifics include teclistamab and elranatamab.

Despite emerging treatments, unmet needs remain, including CAR T-cell accessibility, capacity for bispecific antibodies, managing renal dysfunction and frailty, post-BCMA progression, and high-risk cytogenetics.

Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.